



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/844,935	04/27/2001	Alexander Munishkin	Q01/08C	4219

7590 08/14/2003

Attention: Anthony J. Janiuk, Esq.  
Q-RNA, Inc.  
Suite 408  
3960 Broadway  
New York, NY 10032

EXAMINER

CHAKRABARTI, ARUN K

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 08/14/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/844,935

Applicant(s)

Muniskin

Examiner

Arun Chakrabarti

Art Unit

1634



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on Jun 13, 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-8, 11, and 12 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-8, 11, and 12 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☒ Other: Detailed Action

Art Unit: 1634

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 13, 2003 has been entered.

### ***Specification***

2. Claims 1, 8, 11, and 12 have been amended.

### ***Claim Rejections - 35 USC § 112***

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-8, 11 and 12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1634

Regarding claims 1, 8, 11 and 12, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

***Claim Rejections - 35 USC § 103***

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 1-8 are rejected under 35 U.S.C. 103(a) over Marsh et al.(Nucleic Acids Research, (1988), 16 (3), pages 981-995) in view of Spiegelman (U.S. Patent 3,444,043) (May 13, 1969) further in view of Holy et al. (U.S. Patent 5,977,061) (November 2, 1999).

Art Unit: 1634

Marsh et al. teaches a method of determining the presence or absence of a target molecule (abstract) comprising the steps of:

a) providing a first RNA molecule which can bind to a target molecule and has the formula:

5'-A-B-C-D-E-3'; (Figure 1, 2 and 4)

wherein A is a section of the RNA molecule having 10-10,000 nucleotides which section is, with another sequence, E, replicated by an RNA replicase, the letter "B" denotes a section of the RNA molecule having approximately 1 to 50000 nucleotides which section, with another sequence D, binds the target molecule under binding conditions, the letter "C" denotes a section of the RNA molecule having approximately 1 to 10000 nucleotides, the letter "D" denotes a section of the RNA molecule having approximately 1 to 50000 nucleotides which section, with another B, binds the target molecule under binding conditions, the section B and D, in combination, comprise in total at least 10 nucleotides, the first RNA molecule, with sections B and D bound to target, is acted upon by the RNA replicase to form a second RNA molecule, said second RNA molecule has the following formula:

5'-E'-X-A'-3';

wherein, E' is the complement to E, and A' is the complement to A, and the letter "X" denotes the complement of parts of the sections B and D which may be replicated, or the letter denotes the direct bond between sections E' and A', and second RNA molecule is replicated by the RNA

Art Unit: 1634

replicase under replicating conditions and combining first RNA molecule with a sample (Figure 1, 2, 3 and 4 and Materials and Methods, page 983, lines 12-25);

b) imposing binding conditions on a sample potentially containing target molecules in the presence of first RNA molecule, in the presence of the target molecule, first RNA molecules forms a target-first RNA molecule complex to form a first modified sample (Figure 2, 3 and 4 );

c) imposing RNA replicase reaction conditions on the first modified sample, in the presence of an RNA replicase, to form second RNA molecule in the presence of target to make a second modified sample (Materials and Methods, page 983, lines 12-25);

d) monitoring second modified sample for the presence of the second RNA molecule or its complement, which presence or absence is indicative of the presence or absence of the target molecule (Materials and Methods, page 983, lines 25-32 and Table 1).

Marsh et al. teaches that section "C" may serve as a non base-paired spacer to facilitate access of the replicase to the promoter (page 990, lines 9-10).

Marsh et al. does not teach a composition by providing paired RNA molecules.

Marsh et al does not teach section "C" of the RNA molecule which section is capable of preventing the replication of the first molecule by the RNA replicase (abstract and column 7, lines 8-44).

Spiegelman teaches the customized preparation of RNA templates as he states, "An RNA template of an in vitro replicating system may be formed in situ. If one were, for example, to introduce foreign bases or nucleotides (e.g., analogues of known bases or nucleotides) into the

Art Unit: 1634

replicating system, a mutant may be formed which would be the biologically active template for replication with those same bases or nucleotides, in such instances, one would be synthesizing mutants in vitro in a known way (Column 5, lines 1-8)".

Spiegelman teaches section "C" of the RNA molecule which section is capable preventing the replication of the first molecule by the RNA replicase (abstract and column 7, lines 8-44).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to substitute RNA template model of Spiegelman as the identification of target molecule in the method of Marsh et al., since Spiegelman et al. states "There is good evidence that the replicase recognizes the particular sequence of nucleotides at the beginning and at the end of the biologically active viral RNA template during the course of the replication. It is inferred from this recognition pattern that the intermediate portion of the RNA template is not essential to the direction of or instruction found in the replication mechanism studied. This suggests that the recognition sequences of nucleotides present at the beginning and end of a biologically active RNA template molecule can be selectively bonded to otherwise non-biologically active or non-viral RNA to produce a synthesized biologically active RNA product. It is thought that the RNA forms a circle and these two recognition sequences of the molecule overlap each other to provide double-stranded regions: such overlapped regions could afford, therefore, identification of the RNA molecule in a single, rapid scanning process (Column 4, lines 59-75)". An ordinary practitioner would have been motivated to combine the model of custom made RNA template of Spiegelman into the method of Marsh et al. in order to achieve the

Art Unit: 1634

express advantages noted by Spiegelman of a method which can provide identification of the RNA molecule in a single, rapid scanning process.

Marsh et al. in view of Spiegelman do not teach the nucleic acid, wherein the target is a small or large organic molecule such as a peptide, protein, and derivatives thereof, although Spiegelman suggests analogues of known bases or nucleotides may be incorporated in the RNA molecule at suitable positions.

Holy et al teaches the nucleic acid, wherein the target is a small or large organic molecule such as a peptide, protein, and derivatives thereof, which can be attached to the analogues of known bases or nucleotides (Column 12, line 49 to Column 13, line 2).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the nucleic acid, wherein the target is a small or large organic molecule such as a peptide, protein, and derivatives thereof, which can be attached to the analogues of known bases or nucleotides of Holy et al as the identification of target molecule in the method of Marsh et al in view of Spiegelman et al. since Holy et al. states "In one embodiment of this alternative, antibodies are raised against the compounds of this invention. Such antibodies bind to the analogue of this invention and thereby are useful in detecting its presence as label for a protein or oligonucleotide (Column 12, line 64 to Column 13, line 2)". An ordinary practitioner would have been motivated to combine and substitute the nucleic acid, wherein the target is a small or large organic molecule such as a peptide, protein, and derivatives thereof, which can be attached to the analogues of known bases or nucleotides of Holy et al as



Art Unit: 1634

the identification of target molecule in the method of Marsh et al in view of Spiegelman et al. in order to achieve the express advantages, as noted by Holy et al., of nucleotide analogue which are useful in detecting its presence as label for a protein.

7. Claims 11 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Marsh et al.(Nucleic Acids Research, (1988), 16 (3), pages 981-995) in view of Spiegelman (U.S. Patent 3,444,043) (May 13, 1969) further in view of Holy et al. (U.S. Patent 5,977,061) (November 2, 1999) further in view of Stratagene Catalog (1988, Page 39).

Marsh et al. in view of Spiegelman further in view of Holy et al. teach the compositions of claims 1-8 as described above in detail.

Marsh et al. in view of Spiegelman further in view of Holy et al. do not teach the motivation to combine all the reagents for detecting an analyte in a sample in the form of a kit.

Stratagene catalog teaches a motivation to combine reagents into kit format (page 39).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the compositions of claims 1-8 of Marsh et al. in view of Spiegelman further in view of Holy et al. into a kit format as discussed by Stratagene catalog since the Stratagene catalog teaches a motivation for combining reagents of use in an assay into a kit, "Each kit provides two services: 1) a variety of different reagents have been assembled and pre-mixed specifically for a defined set of experiments. Thus one need not purchase gram quantities of 10 different reagents, each of which is needed in only microgram amounts, when beginning a series of experiments. When one considers all of the unused chemicals that typically

Art Unit: 1634

accumulate in weighing rooms, desiccators, and freezers, one quickly realizes that it is actually far more expensive for a small number of users to prepare most buffer solutions from the basic reagents. Stratagene provides only the quantities you will actually need, premixed and tested. In actuality, the kit format saves money and resources for everyone by dramatically reducing waste.

2) The other service provided in a kit is quality control (page 39, column 1).

***Response to Amendment***

8. In response to amendment, previous 102(b) and 103(a) rejections are withdrawn. However, new 103(a) rejections are hereby included.

***Response to Arguments***

9. Applicant's arguments with respect to all pending claims have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D. whose telephone number is (703) 306-5818.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. Any inquiry of a general nature or

Art Unit: 1634

relating to the status of this application should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission via the P.T.O. Fax Center located In Crystal Mall 1. The CM1 Fax Center numbers for Technology Center 1600 are either (703) 305-3014 or (703) 308-4242. Please note that the faxing of such papers must conform with the Notice to Comply published In the Official Gazette, 1096 OG 30 (November 15, 1989).

Arun Chakrabarti

Patent Examiner

Art Unit 1634,

July 29, 2003

  
**ARUN K. CHAKRABARTI**  
**PATENT EXAMINER**